Create Free Account

By creating account you will get access to hot stocks & personalised emails

Compumedics Ltd

Healthcare AU CMP

0.29AUD
-(-%)

Last update at 2024-11-13T03:19:00Z

Day Range

0.290.29
LowHigh

52 Week Range

0.150.45
LowHigh

Fundamentals

  • Previous Close 0.29
  • Market Cap56.05M
  • Volume65000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.24M
  • Revenue TTM50.26M
  • Revenue Per Share TTM0.28
  • Gross Profit TTM 22.11M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.71900M 1.70M 0.78M -7.50300M 5.07M
Minority interest - - - - -
Net income -6.12200M 1.36M 1.00M -5.83800M 3.99M
Selling general administrative 6.41M 5.64M 6.12M 5.93M 6.42M
Selling and marketing expenses 13.25M 9.48M 8.26M 9.00M 8.47M
Gross profit 21.59M 19.29M 19.16M 18.01M 24.75M
Reconciled depreciation 1.01M 1.21M 1.46M 1.66M 0.43M
Ebit -2.97900M 2.10M -0.35100M -1.08600M 5.33M
Ebitda -1.96600M 2.61M 1.11M 0.58M 5.88M
Depreciation and amortization 1.01M 0.51M 1.46M 1.66M 0.55M
Non operating income net other - - - - -
Operating income -3.01900M 0.99M 0.96M -0.39800M 5.33M
Other operating expenses -7.35400M 0.36M -1.47800M -8.03800M 37.51M
Interest expense 0.65M 0.40M 0.33M 0.42M 0.26M
Tax provision -0.59700M 0.34M -0.22200M -1.66500M 1.07M
Interest income 0.61M 0.23M 1.14M 0.42M 0.26M
Net interest income -0.65200M -0.40100M -0.33000M -0.42000M -0.26100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.59700M 0.34M -0.22200M -1.66500M 1.08M
Total revenue 42.41M 37.76M 35.74M 35.07M 41.51M
Total operating expenses 26.14M 19.69M 18.76M 18.77M 20.76M
Cost of revenue 20.82M 18.46M 16.58M 17.06M 16.75M
Total other income expense net -2.53300M 1.99M 0.71M -6.32700M -0.26100M
Discontinued operations - - - - -
Net income from continuing ops -6.12200M 1.36M 1.00M -5.83800M 4.02M
Net income applicable to common shares -6.12200M 1.36M 1.00M -5.83800M 4.02M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 40.15M 41.18M 41.49M 38.55M 35.53M
Intangible assets - 6.24M 6.45M 4.08M 2.78M
Earning assets - - - - -
Other current assets 0.71M 2.43M 2.35M 2.47M 1.05M
Total liab 22.13M 22.89M 17.90M 16.39M 13.73M
Total stockholder equity 18.02M 18.29M 23.59M 22.16M 21.79M
Deferred long term liab - 6.24M 6.45M 4.08M 2.78M
Other current liab 4.46M 4.26M 3.51M 3.15M 2.93M
Common stock 35.65M 35.65M 35.65M 35.65M 35.65M
Capital stock - 35.65M 35.65M 35.65M 35.65M
Retained earnings -17.47300M -17.79100M -11.66900M -13.02600M -13.90200M
Other liab - 0.14M 0.20M 0.29M 0.45M
Good will - - - - -
Other assets - 1.10M 6.95M 4.90M 3.56M
Cash 1.89M 3.80M 7.08M 6.77M 6.41M
Cash and equivalents - - 7.08M - -
Total current liabilities 21.22M 21.19M 17.32M 15.35M 12.44M
Current deferred revenue 1.34M 2.69M 1.92M 1.75M 1.72M
Net debt 6.68M 5.67M -0.74700M -0.95000M -1.61300M
Short term debt 7.72M 7.91M 5.95M 5.07M 3.95M
Short long term debt - 7.22M 5.80M 4.41M 3.05M
Short long term debt total 8.56M 9.47M 6.33M 5.82M 4.80M
Other stockholder equity -0.16500M -17.86300M -23.98500M -22.62800M -21.63000M
Property plant equipment - 3.62M 1.21M 1.71M 3.08M
Total current assets 25.95M 29.52M 33.33M 31.93M 28.89M
Long term investments - 0.70M - - -
Net tangible assets - 18.29M 23.59M 22.16M 21.79M
Short term investments - - - - -
Net receivables 10.45M 12.53M 14.12M 13.01M 12.60M
Long term debt - 0.20M 0.38M 0.59M 0.01M
Inventory 12.91M 10.69M 9.71M 9.68M 8.83M
Accounts payable 7.70M 6.33M 5.94M 5.38M 3.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.43M -0.39400M -0.47300M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - - - 35.65M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 10.16M - -1.21300M -1.71100M -3.08300M
Deferred long term asset charges - - - - -
Non current assets total 14.20M 11.66M 8.16M 6.61M 6.64M
Capital lease obligations - 2.04M 0.15M 0.82M 1.74M
Long term debt total - 1.56M 0.38M 0.75M 0.85M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -4.40800M -2.95900M -1.84300M -4.23300M -4.28600M
Change to liabilities 0.49M 0.92M 1.40M -1.68800M 0.22M
Total cashflows from investing activities -4.40800M -2.95900M -1.55400M -4.23300M -4.28600M
Net borrowings -1.00500M 1.28M -0.17900M 0.45M 0.15M
Total cash from financing activities -1.00500M 1.28M -0.17900M 0.45M 0.15M
Change to operating activities 0.68M 0.52M -1.11800M 0.79M 0.18M
Net income -6.12200M 1.36M 1.00M -5.83800M 3.99M
Change in cash -4.99400M 1.94M -0.87300M 1.64M 1.17M
Begin period cash flow 7.29M 5.14M 6.01M 4.37M 3.20M
End period cash flow 2.30M 7.08M 5.14M 6.01M 4.37M
Total cash from operating activities 0.05M 3.29M 1.32M 5.38M 5.14M
Issuance of capital stock - - - - -
Depreciation 0.98M 1.13M 1.37M 1.48M 0.55M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.98100M -0.03000M -0.84700M -1.03300M -0.23700M
Change to account receivables 1.51M -0.98700M -0.41500M 3.38M 0.47M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.14500M 3.83M -0.12100M 2.03M 0.88M
Change to netincome 3.37M 0.60M -0.04100M 8.01M -0.00200M
Capital expenditures 4.41M 2.96M 1.84M 4.23M 4.29M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.53M -1.01700M -1.26200M 2.35M 0.40M
Stock based compensation - - - - -
Other non cash items 4.66M 1.81M 0.22M 7.39M -4.44400M
Free cash flow -4.35900M 0.33M -0.51900M 1.15M 0.85M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CMP
Compumedics Ltd		 - -% 0.29 - - 1.12 3.08 1.26 22.49
COH
Cochlear Ltd		 -2.48 0.83% 296.93 53.21 47.17 8.48 10.35 8.40 32.43
PNV
Polynovo Ltd		 - -% 2.06 208.00 135.14 13.92 19.54 13.36 340.64
AVH
Avita Therapeutics Inc		 0.14 3.80% 3.82 - - 8.76 12.74 5.31 -10.0538
EBR
Ebr Systems Inc CDR		 0.01 1.48% 1.03 - - - 21.41 - -3.6785

Reports Covered

Stock Research & News

View All

Profile

Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the United States, and Europe. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Okti; Grael PSG; Grael 4K PSG; Falcon PSG; Falcon HST; Somté, an investigative tool; Siesta 802; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, an portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; CURRY, a signal processing and soutce localization multi-modal neuroimaging suite; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, TCM5 FLEX transcutaneous monitors, Grael DC, and persyst software products. Further, the company offers magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; and consumables and supplies for diagnostic and research solutions. Additionally, the company provides doppler diagnostics; Nuevo LTM EEG; Orion LifeSpan MEG; and quick-cap EEG electrode arrays. Compumedics Limited was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.

Compumedics Ltd

30-40 Flockhart Street, Abbotsford, VIC, Australia, 3067

Key Executives

Name Title Year Born
Dr. David Burton Ph.D. Founder, Exec. Chairman, CEO & Member of Medical Advisory Board 1959
Mr. David Francis Lawson CFO, Company Sec. & Exec. Director 1965
Mr. Warwick Freeman Chief Technology Officer NA
Mr. Christoph Witte Gen. Managing of Director DWL Compumedics Germany GmbH NA
Dr. Kerry Trent Hubick Legal Counsel and Trademark, Patent & Gen. Legal Attorney NA
Dr. Curtis Ponton Chief Scientist of Neuroscan & VP NA
Mr. Paul Spooner Bus. Director of EMEA NA
Dr. David Burton Ph.D. Founder, Executive Chairman, CEO & Member of Medical Advisory Board 1959
Mr. David Francis Lawson CFO, Company Secretary & Executive Director 1965
Dr. Kerry Trent Hubick Legal Counsel and Trademark, Patent & General Legal Attorney NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.